Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma

Maria Debora De Pasquale, Rosanna Pessolano, Renata Boldrini, Ilaria Ilari, Alberto Donfrancesco, Enrico Cortesi, Alessandro Jenkner

Research output: Contribution to journalArticle

Abstract

A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination. Treatment was well tolerated, but the patient developed hypothyroidism and significant hypertension with bevacizumab and sunitinib. She responded to all agents and was given radiation treatment twice at the time of symptomatic disease progression; she died 33 months from diagnosis.

Original languageEnglish
JournalJournal of Pediatric Hematology/Oncology
Volume33
Issue number5
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Renal Cell Carcinoma
Protein-Tyrosine Kinases
Hypothyroidism
Nephrectomy
Interferons
Disease Progression
Radiation
Hypertension
Therapeutics
sunitinib
Bevacizumab
sorafenib
Everolimus

Keywords

  • childhood
  • Renal cell carcinoma
  • targeted therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma. / De Pasquale, Maria Debora; Pessolano, Rosanna; Boldrini, Renata; Ilari, Ilaria; Donfrancesco, Alberto; Cortesi, Enrico; Jenkner, Alessandro.

In: Journal of Pediatric Hematology/Oncology, Vol. 33, No. 5, 07.2011.

Research output: Contribution to journalArticle

@article{3729d6014c9641eaa41453dac513b4f0,
title = "Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma",
abstract = "A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination. Treatment was well tolerated, but the patient developed hypothyroidism and significant hypertension with bevacizumab and sunitinib. She responded to all agents and was given radiation treatment twice at the time of symptomatic disease progression; she died 33 months from diagnosis.",
keywords = "childhood, Renal cell carcinoma, targeted therapy",
author = "{De Pasquale}, {Maria Debora} and Rosanna Pessolano and Renata Boldrini and Ilaria Ilari and Alberto Donfrancesco and Enrico Cortesi and Alessandro Jenkner",
year = "2011",
month = "7",
doi = "10.1097/MPH.0b013e3182028fd9",
language = "English",
volume = "33",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma

AU - De Pasquale, Maria Debora

AU - Pessolano, Rosanna

AU - Boldrini, Renata

AU - Ilari, Ilaria

AU - Donfrancesco, Alberto

AU - Cortesi, Enrico

AU - Jenkner, Alessandro

PY - 2011/7

Y1 - 2011/7

N2 - A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination. Treatment was well tolerated, but the patient developed hypothyroidism and significant hypertension with bevacizumab and sunitinib. She responded to all agents and was given radiation treatment twice at the time of symptomatic disease progression; she died 33 months from diagnosis.

AB - A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination. Treatment was well tolerated, but the patient developed hypothyroidism and significant hypertension with bevacizumab and sunitinib. She responded to all agents and was given radiation treatment twice at the time of symptomatic disease progression; she died 33 months from diagnosis.

KW - childhood

KW - Renal cell carcinoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=79959817730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959817730&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e3182028fd9

DO - 10.1097/MPH.0b013e3182028fd9

M3 - Article

VL - 33

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 5

ER -